TNF and tuberculosis: In a systematic review conducted by Goletti et al., they concluded non-anti-TNF targeted biologics usage, proper LTBI screening investigations, and adequate preventive TB therapy had the opportunity to reduce the risk of TB reactivation in rheumatic patients requiring biological drugs [11].